Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  The Oncologist

• Publication date

  2011-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1634/theoncologist.2010-0248PMID 21478275PMCID PMC3228192
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Axonal ion channels from bench to bedside: a translational neuroscience perspective.

  2009cited by this paper
• NCCN task force report: management of neuropathy in cancer.

  2009cited by this paper
• Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.

  2009cited by this paper
• Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.

  2009cited by this paper
• Persistent neuropathy after treatment with cisplatin and oxaliplatin

  2009cited by this paper
• Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

  2009cited by this paper
• Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

  2007cited by this paper
• The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy‐induced peripheral neurotoxicity: comparison with the National Cancer Institute‐Common Toxicity Scale

  2007cited by this paper
• Persistence of High-Dose Oxaliplatin-Induced Neuropathy at Long-Term Follow-Up

  2006cited by this paper
• Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicity

  2006cited by this paper
• Oxaliplatin and Axonal Na+ Channel Function In vivo

  2006cited by this paper
• The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.

  2005cited by this paper
• Oxaliplatin‐induced neurotoxicity and the development of neuropathy

  2005cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

  2004cited by this paper
• Oxaliplatin‐induced neurotoxicity: Acute hyperexcitability and chronic neuropathy

  2004cited by this paper
• Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory.

  2003cited by this paper
• Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale

  2003cited by this paper
• Oxaliplatin-safety profile: neurotoxicity.

  2003cited by this paper
• CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.

  2003cited by this paper
• Thalidomide-induced neuropathy

  2002cited by this paper
• Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures.

  2002cited by this paper
• Clinical evaluation of excitability measures in sensory nerve

  2001cited by this paper
• Excitability of human axons.

  2001cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Multiple measures of axonal excitability: A new approach in clinical testing

  2000cited by this paper
• Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

  1999cited by this paper
• Total neuropathy score

  1999cited by this paper
• Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.

  1998cited by this paper
• Oxaliplatin: mechanism of action and antineoplastic activity.

  1998cited by this paper
• Threshold tracking techniques in the study of human peripheral nerve

  1998cited by this paper
• The Rochester Diabetic Neuropathy Study

  1992cited by this paper
• Electrodiagnosis in diseases of nerve and muscle.

  1984cited by this paper
• Sensory conduction of the sural nerve in polyneuropathy1

  1974cited by this paper

• Oxaliplatin reversibly and differentially affects electrogenic activity of small IB4(+) of male and female rat sensory neurons.

  2025cites this paper
• Epidemiology and clinical significance of chemotherapy-induced peripheral neuropathy in patients undergoing chemotherapy

  2025cites this paper
• Programme pilote de rééducation sensitive des neuropathies périphériques induites par la chimiothérapie (NPIC) auprès d’une clientèle oncologique

  2025cites this paper
• Hyperalgesic Priming in the Transition From Acute to Chronic Pain: Focus on Different Models and the Molecular Mechanisms Involved

  2025cites this paper
• Effect of Chemotherapy-Induced Peripheral Neuropathy Symptom Permanence on Patient's Preference to Alter or Continue Neurotoxic Chemotherapy Treatment

  2025cites this paper
• Mixed-methods Study of the Effect of Chemotherapy-induced Peripheral Neuropathy SymptomPermanence on Patient’s Willingness to Alter Neurotoxic Chemotherapy Treatment

  2025cites this paper
• Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial

  2025cites this paper
• Systemic anti‐cancer therapy and anaesthesia: a narrative review

  2025cites this paper
• Funktionelle Folgen von Radiotherapie, Chemotherapie und Operation bei der Behandlung des Rektumkarzinoms

  2025cites this paper
• Effects of exercise on paclitaxel-induced peripheral neuropathy in patients with cancer: A systematic review and meta-analysis

  2025cites this paper
• Existing problems of prevention and treatment of chemo-induced peripheral neuropathy: world experience and own data

  2024cites this paper
• Oxaliplatin-induced Acute Neurotoxicity Recovers Between Repeat Infusion Cycles: An Axonal Excitability Repeated Multiple Measurements Study.

  2024cites this paper
• Vitamin B6 status and chronic chemotherapy-induced peripheral neuropathy: a prospective cohort study among patients with non-metastatic colorectal cancer receiving oxaliplatin-based chemotherapy

  2024cites this paper
• The Association between Oxaliplatin-Induced Peripheral Neuropathy, Sociodemographic, and Clinical Characteristics with Falls in Older Adults with Colorectal Cancer.

  2024cites this paper
• A qualitative evaluation of the oncologists’, neurologists’, and pain specialists’ views on the management and care of chemotherapy-induced peripheral neuropathy in The Netherlands

  2024cites this paper
• Discovery and preclinical evaluation of a novel inhibitor of FABP5, ART26.12, effective in Oxaliplatin-induced Peripheral Neuropathy.

  2024cites this paper
• The association between sociodemographic, clinical, and potentially preventive therapies with oxaliplatin-induced peripheral neuropathy in colorectal cancer patients

  2023cites this paper
• Patient-reported unmet supportive care needs in long-term colorectal cancer survivors after curative treatment in an asian population.

  2023cites this paper
• Electrophysiologic Characteristics of Nitrous-Oxide-Associated Peripheral Neuropathy: A Retrospective Study of 76 Patients

  2023cites this paper
• Multi-Disciplinary Management in Rectal Cancer Survivorship: A Clinical Practice Review

  2023cites this paper
• Role of pattern recognition receptors in chemotherapy-induced neuropathic pain.

  2023cites this paper
• S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma–final results of the randomized AIO MATEO phase II trial

  2023cites this paper
• Efficacy of donepezil for the treatment of oxaliplatin-induced peripheral neuropathy: DONEPEZOX, a protocol of a proof of concept, randomised, triple-blinded and multicentre trial

  2022cites this paper
• DFT Study on the Substituent Effect of Anticancer Picoline-Diazido-Pt(IV) Compounds

  2022cites this paper
• Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis

  2022cites this paper
• Is CT-based body composition associated with long-term chemotherapy-induced peripheral neuropathy in colorectal cancer survivors?

  2022cites this paper
• A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy

  2022cites this paper
• Quantitative proteomic analysis of oxaliplatin induced peripheral neurotoxicity.

  2022cites this paper
• Efficacy of Traditional Chinese Medicine Injection in Preventing Oxaliplatin-Induced Peripheral Neurotoxicity: An Analysis of Evidence from 3598 Patients

  2022cites this paper
• Bridging the Translational Gap in Chemotherapy-Induced Peripheral Neuropathy with iPSC-Based Modeling

  2022cites this paper
• Neuroendocrine mechanisms in oxaliplatin-induced hyperalgesic priming

  2022cites this paper
• Capsaicin 8% patch Qutenza and other current treatments for neuropathic pain in chemotherapy-induced peripheral neuropathy (CIPN)

  2021cites this paper
• Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy (CIPN) in CTEP-sponsored phase I trials

  2021cites this paper
• α-Conotoxin RgIA and oligoarginine R8 in the mice model alleviate long-term oxaliplatin induced neuropathy.

  2021cites this paper
• Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial

  2021cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Epidemiology, Pathomechanisms and Treatment

  2021cites this paper
• Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study

  2021cites this paper
• Dorsal Root Ganglion Morphometric Changes Under Oxaliplatin Treatment

  2021cites this paper
• Chemotherapy and peripheral neuropathy

  2021cites this paper
• Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer

  2021cites this paper
• Probing the peripheral immune response in mouse models of oxaliplatin-induced peripheral neuropathy highlights their limited translatability

  2021influential citation
• Patient demographics and management landscape of metastatic colorectal cancer in the third‐line setting: Real‐world data in an australian population

  2021cites this paper
• Epigenetics Involvement in Oxaliplatin-Induced Potassium Channel Transcriptional Downregulation and Hypersensitivity

  2021cites this paper
• Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms

  2021cites this paper
• Clinical and biochemical markers in CIPN: A reappraisal.

  2021cites this paper
• The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors

  2021cites this paper
• Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy

  2021cites this paper
• AAAPT Diagnostic Criteria for Acute Neuropathic Pain.

  2021cites this paper
• Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response.

  2021cites this paper
• Approach to chemotherapy-induced peripheral neuropathy

  2021cites this paper
• Qualitative Evaluation of the Influence of Acute Oxaliplatin‐Induced Peripheral Neuropathy on Quality of Life and Activities of Daily Life

  2020cites this paper
• Neurologic Complications

  2020cites this paper
• Symptom Experiences in Colorectal Cancer Survivors After Cancer Treatments

  2020cites this paper
• Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series

  2020cites this paper
• Measurement of axonal excitability: Consensus guidelines.

  2020cites this paper
• Electrophysiological and phenotypic profiles of taxane-induced neuropathy.

  2020cites this paper
• Long‐term symptoms of polyneuropathy in breast and colorectal cancer patients treated with and without adjuvant chemotherapy

  2020cites this paper
• Chronic defects in intraspinal mechanisms of spike encoding by spinal motoneurons following chemotherapy.

  2020cites this paper
• Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1

  2020cites this paper
• Bexarotene normalizes chemotherapy-induced myelin decompaction and reverses cognitive and sensorimotor deficits in mice

  2020cites this paper
• Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

  2020cites this paper
• Total Neoadjuvant Therapy for Rectal Cancer: Current Status and Future Directions

  2020cites this paper
• The relevance of multimodal assessment in experimental oxaliplatin-induced peripheral neurotoxicity.

  2020cites this paper
• Non-randomized preliminary study of an education and elastic-band resistance exercise program on severity of neuropathy, physical function, muscle strength and endurance & quality of life in colorectal cancer patients experiencing oxaliplatin-induced peripheral neuropathy.

  2020cites this paper
• Imbalanced Subthreshold Currents Following Sepsis and Chemotherapy: A Shared Mechanism Offering a New Therapeutic Target?

  2020cites this paper
• A Comparative Review of Chemotherapy-Induced Peripheral Neuropathy in In Vivo and In Vitro Models

  2020cites this paper
• Long-Term Effects of Colorectal Carcinoma in Childhood and Adolescents

  2020cites this paper
• Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study

  2020cites this paper
• Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy‐induced peripheral neuropathy: A mediation effect analysis

  2019cites this paper
• Adjuvant chemotherapy in stage II–III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX

  2019cites this paper
• Chemotherapy-induced peripheral neuropathy and its association with quality of life among cancer patients

  2019cites this paper
• Early changes in tests of peripheral nerve function during oxaliplatin treatment and their correlation with chemotherapy‐induced polyneuropathy symptoms and signs

  2019cites this paper
• Mechanisms of Chemotherapy-Induced Peripheral Neuropathy

  2019cites this paper
• Animal models of chemotherapy-induced peripheral neuropathy: A machine-assisted systematic review and meta-analysis

  2019cites this paper
• Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence

  2019cites this paper
• Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program-sponsored phase I trials.

  2019cites this paper
• Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning

  2019cites this paper
• Analgesic Effect of Melittin on Oxaliplatin-Induced Peripheral Neuropathy in Rats

  2019cites this paper
• Inflammatory and neuropathic gene expression signatures of chemotherapy-induced neuropathy induced by vincristine, cisplatin and oxaliplatin in C57BL/6J mice.

  2019cites this paper
• Fahreignung onkologischer Patienten

  2019cites this paper
• Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy.

  2019cites this paper
• Differential protein expression profiling by iTRAQ‐2D‐LC‐MS/MS of rats treated with oxaliplatin

  2019cites this paper
• A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers

  2019cites this paper
• Prevalence and characteristics of neuropathy in carcinoma colon patients on FOLFOX4 therapy

  2019cites this paper
• Quality of Life in patients treated with Taxane monotherapy

  2019cites this paper
• Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy

  2019cites this paper
• Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment

  2019cites this paper
• Early sensory neurophysiological changes in prediabetes

  2019cites this paper
• Prophylaxe und Therapie der chemotherapieinduzierten Polyneuropathie

  2018cites this paper
• Chronic Pain and Neuropathy Following Adjuvant Chemotherapy

  2018cites this paper
• Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis

  2018cites this paper
• Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy

  2018cites this paper
• Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.

  2018cites this paper
• The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial.

  2018cites this paper
• A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.

  2018cites this paper
• A‐Fibers Mediate Cold Hyperalgesia in Patients with Oxaliplatin‐Induced Neuropathy

  2018cites this paper
• Reliability and validity of the Chinese version neuropathic pain symptom inventory in patients with colorectal cancer.

  2018cites this paper
• Balance and Gait Impairment: Sensor‐based assessment for patients with peripheral neuropathy

  2018cites this paper
• Total neoadjuvant therapy for rectal cancer.

  2018cites this paper
• Oxaliplatin‐induced enteric neuronal loss and intestinal dysfunction is prevented by co‐treatment with BGP‐15

  2018cites this paper